Abstract
Aim: To explore the effect of rituximab in combination with chemotherapy in treating diffuse large B-cell lymphoma,and levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells.
Methods: 80 patients admitted to Lujiang County People’s Hospital from January 2022 to January 2024 were included. The control group accepted cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen. On the basis of the control group, the research group was treated with rituximab. Serum related factors. 4 mL of fasting venous blood was obtained from patients. After centrifugation, the serum was separated. The levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) along with interleukin-6 (IL-6) were detected by RT-96A enzyme marker (Shenzhen Mindrays Medical Electronics Co., LTD.). The ELISA kit was purchased from Shenzhen Jingmei Biotechnology Co., LTD. Lymphocyte subsets index. Blood samples of the two groups were collected, and the plasma T cells, NK cells as well as B cells of the two groups were detected by flow cytometry.
Results: The total clinical effective rate of the research group was better relative to the control group (P<0.05). After therapy, compared to the control group, vascular endothelial growth factor, thymidine kinase 1, and interleukin-6 levels in the research group presented lower (P<0.05), plasma T cells, natural killer cells along with B cells in the research group presented lower (P<0.05), and Quality of Life Core Questionnaire-Core 30 scores in the research group presented higher (P<0.05). No difference was seen in the occurrence of adverse reactions between 2 groups (P>0.05).
Conclusion: In conclusion, Rtuximab in combination with chemotherapy patients can promote the therapeutic effect, lessen the level of serum related factors, promote the immune function, as well as promote the quality of life in patients with diffuse large B-cell lymphoma.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.